{"title_page": "HT-2157", "text_new": "{{Drugbox\n| IUPAC_name = 1-Phenyl-3-[3-(trifluoromethyl)phenyl]iminoindol-2-one\n| image = HT-2157_formula_skeletal.svg\n| alt = Structural formula\n| width = 210\n| image2 = HT-2157 molecule spacefill.png\n| alt2 = Space-filling model\n| width2 = 190\n\n<!--Clinical data-->\n| tradename =  \n| pregnancy_category =  \n| legal_status = \n| routes_of_administration =\n\n<!--Pharmacokinetic data-->\n| bioavailability =  \n| metabolism =  \n| elimination_half-life =  \n| excretion =\n\n<!--Identifiers-->\n| IUPHAR_ligand = 6126\n| CAS_number = 303149-14-6\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = J4DRJ9BFS1\n| ATC_prefix = none\n| ATC_suffix =  \n| PubChem = 1471834\n|  ChemSpiderID = 1213983\n\n<!--Chemical data-->\n| C=21 | H=13 | F=3 | N=2 | O=1 \n| smiles = c14ccccc4n(-c3ccccc3)c(=O)c1=N\\c(c2)cccc2C(F)(F)F\n|  StdInChI = 1S/C21H13F3N2O/c22-21(23,24)14-7-6-8-15(13-14)25-19-17-11-4-5-12-18(17)26(20(19)27)16-9-2-1-3-10-16/h1-13H/b25-19+\n|  StdInChIKey = TXCGMRVPXUBHAL-NCELDCMTSA-N\n\n}}\n\n'''HT-2157''' (former development code '''SNAP-37889''') is a drug which acts as a selective non-peptide [[receptor antagonist|antagonist]] for the receptor [[Galanin receptor 3|GAL-3]], which is usually activated by the [[neuropeptide]] [[galanin]]. Blocking this receptor with HT-2157 produced increased [[serotonin]] release,<ref>{{Cite web|url=http://www.pa2online.org/abstract/abstract.jsp?abid=28301|title=pA2 Online|website=www.pa2online.org}}</ref> as well as producing [[antidepressant]] and [[anxiolytic]] effects in animal studies,<ref>{{cite journal | vauthors = Swanson CJ, Blackburn TP, Zhang X, Zheng K, Xu ZQ, H\u00f6kfelt T, Wolinsky TD, Konkel MJ, Chen H, Zhong H, Walker MW, Craig DA, Gerald CP, Branchek TA | display-authors = 6 | title = Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299 | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 102 | issue = 48 | pages = 17489\u201394 | date = November 2005 | pmid = 16287967 | pmc = 1283534 | doi = 10.1073/pnas.0508970102 }}</ref> and it was also being researched for treatment of [[cognitive dysfunction]].<ref>{{Cite patent | inventor = Kaplan AP | title = Enteric-coated HT-2157 compositions and methods of their use | country = US | number = 8277842 | pubdate = January 20, 2012 }}</ref> All human clinical trials were terminated due to safety concerns however, and new GAL-3 antagonists are now being sought instead.<ref name=\"DartNeuroScience\">{{Cite web|url=http://www.dartneuroscience.com/DrugPrograms.php|title=Dart NeuroScience LLC -- Scientific Advisory Board|website=www.dartneuroscience.com}}</ref>\n\n== References ==\n{{Reflist|2}}\n\n{{Neuropeptidergics}}\n\n[[Category:Peptides]]\n[[Category:Receptor antagonists]]\n[[Category:Abandoned drugs]]\n[[Category:Trifluoromethyl compounds]]\n\n{{nervous-system-drug-stub}}\n", "text_old": "{{Drugbox\n| IUPAC_name = 1-Phenyl-3-[3-(trifluoromethyl)phenyl]iminoindol-2-one\n| image = HT-2157_formula_skeletal.svg\n| alt = Structural formula\n| width = 210\n| image2 = HT-2157 molecule spacefill.png\n| alt2 = Space-filling model\n| width2 = 190\n\n<!--Clinical data-->\n| tradename =  \n| pregnancy_category =  \n| legal_status = \n| routes_of_administration =\n\n<!--Pharmacokinetic data-->\n| bioavailability =  \n| metabolism =  \n| elimination_half-life =  \n| excretion =\n\n<!--Identifiers-->\n| IUPHAR_ligand = 6126\n| CAS_number = 303149-14-6\n| ATC_prefix = none\n| ATC_suffix =  \n| PubChem = 1471834\n|  ChemSpiderID = 1213983\n\n<!--Chemical data-->\n| C=21 | H=13 | F=3 | N=2 | O=1 \n| smiles = c14ccccc4n(-c3ccccc3)c(=O)c1=N\\c(c2)cccc2C(F)(F)F\n|  StdInChI = 1S/C21H13F3N2O/c22-21(23,24)14-7-6-8-15(13-14)25-19-17-11-4-5-12-18(17)26(20(19)27)16-9-2-1-3-10-16/h1-13H/b25-19+\n|  StdInChIKey = TXCGMRVPXUBHAL-NCELDCMTSA-N\n\n}}\n\n'''HT-2157''' (former development code '''SNAP-37889''') is a drug which acts as a selective non-peptide [[receptor antagonist|antagonist]] for the receptor [[Galanin receptor 3|GAL-3]], which is usually activated by the [[neuropeptide]] [[galanin]]. Blocking this receptor with HT-2157 produced increased [[serotonin]] release,<ref>{{Cite web|url=http://www.pa2online.org/abstract/abstract.jsp?abid=28301|title=pA2 Online|website=www.pa2online.org}}</ref> as well as producing [[antidepressant]] and [[anxiolytic]] effects in animal studies,<ref>{{cite journal | vauthors = Swanson CJ, Blackburn TP, Zhang X, Zheng K, Xu ZQ, H\u00f6kfelt T, Wolinsky TD, Konkel MJ, Chen H, Zhong H, Walker MW, Craig DA, Gerald CP, Branchek TA | display-authors = 6 | title = Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299 | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 102 | issue = 48 | pages = 17489\u201394 | date = November 2005 | pmid = 16287967 | pmc = 1283534 | doi = 10.1073/pnas.0508970102 }}</ref> and it was also being researched for treatment of [[cognitive dysfunction]].<ref>{{Cite patent | inventor = Kaplan AP | title = Enteric-coated HT-2157 compositions and methods of their use | country = US | number = 8277842 | pubdate = January 20, 2012 }}</ref> All human clinical trials were terminated due to safety concerns however, and new GAL-3 antagonists are now being sought instead.<ref name=\"DartNeuroScience\">{{Cite web|url=http://www.dartneuroscience.com/DrugPrograms.php|title=Dart NeuroScience LLC -- Scientific Advisory Board|website=www.dartneuroscience.com}}</ref>\n\n== References ==\n{{Reflist|2}}\n\n{{Neuropeptidergics}}\n\n[[Category:Peptides]]\n[[Category:Receptor antagonists]]\n[[Category:Abandoned drugs]]\n[[Category:Trifluoromethyl compounds]]\n\n{{nervous-system-drug-stub}}\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/HT-2157"}
